Tyrosine kinase inhibitorPhase 3 trialInvestigational
Cabozantinib
How it works
Blocks the action of multiple tyrosine kinases, including those involved in angiogenesis and cell growth.
Cancer types
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Cabozantinib and Atezolizumab for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing New Treatments for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Preventing Mucosal Melanoma Return After Surgery | Melanoma | phase-2 | — | Source → |
| Testing a New Combination Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining Two Cancer Treatments Shows Promise in Advanced Melanoma | Melanoma | phase-1/2 | Among 20 patients treated in phase 2, the overall response rate was 45%, median progression-free survival was 6.6 months, and median overall survival was 29.5 months. | Source → |
| Cabozantinib Improves Progression-Free Survival in Advanced Neuroendocrine Tumors | Pancreatic Cancer | phase-3 | The median progression-free survival with cabozantinib was 8.4 months in patients with extrapancreatic neuroendocrine tumors and 13.8 months in patients with pancreatic neuroendocrine tumors. | Source → |
| Cabozantinib Linked to Higher Liver Damage Risk in Cancer Patients | Leukemia | meta-analysis | — | Source → |
| New Potential Treatment for Pancreatic Cancer Identified | Pancreatic Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.